Inclusion Criteria:  Diagnosis of  Acute myeloid leukemia (AML) or acute lymphoblastic leukaemia (ALL) in dose-intensive phases of induction/re-induction, intensification or consolidation or Lymphoma in induction or Any disease within 30 days of allogeneic or autologous HSCT Neutropenia (<500 cells/mm3) Afebrile (temperature <38.0°C) period for at least 48 hours and no more than 96 hours after at least one temperature measured by axillary or tympanic thermometer (≥38.0°C) Commenced on empiric FN antibiotics (any of piperacillin-tazobactam, cefepime, ceftazidime or vancomycin and ciprofloxacin)  Exclusion Criteria:  Prolonged febrile neutropenia (documented daily temperature ≥38.0°C for ≥7 day) Documented positive blood culture since onset of FN episode and prior to randomisation Documented other infection (microbiologically or clinically documented) requiring antibiotic treatment since onset of FN episode and prior to randomisation Admitted to the ICU at the time of randomisation Clinical instability (One or more conscious state, respiratory rate, blood pressure, heart rate or oxygen saturations in MET criteria OR two or more respiratory rate, blood pressure, heart rate or oxygen saturations simultaneously (+/- 4 hrs) in the clinical review criteria in 48 hours prior to randomisation) Within 28 days of last randomisation